Journal article
Akt isoform specific effects in ovarian cancer progression
Abstract
Ovarian cancer remains a significant therapeutic problem and novel, effective therapies are needed. Akt is a serine-threonine kinase that is overexpressed in numerous cancers, including ovarian. Mammalian cells express three Akt isoforms which are encoded by distinct genes. Although there are several Akt inhibitors in clinical trials, most indiscriminately target all isoforms. Current in vitro data and animal knockout experiments suggest that …
Authors
Linnerth-Petrik NM; Santry LA; Moorehead R; Jücker M; Wootton SK; Petrik J
Journal
Oncotarget, Vol. 5, No. 0, pp. 74820–74833
Publisher
Impact Journals
Publication Date
November 15, 2016
DOI
10.18632/oncotarget.11204
ISSN
1949-2553
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AnimalsAntineoplastic AgentsApoptosisCell Line, TumorCell ProliferationCell SurvivalDisease Models, AnimalDisease ProgressionFemaleGene Knockdown TechniquesHumansMiceMice, KnockoutNeoplasm MetastasisOvarian NeoplasmsPrognosisProtein IsoformsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktRNA, Small InterferingTumor Burden